Lytix Biopharma AS (FRA:6BG) Tariff Resilience Score: 0/10 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6BG Lytix Biopharma AS FRA:6BG
27 GF Score
Price €0.74
GF Value €0.02
! 1 Warning Sign
View Full Analysis

What is Lytix Biopharma AS Tariff Resilience Score?

Lytix Biopharma AS has the Tariff Resilience Score of 0, which implies that the company might have .

Lytix Biopharma AS has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Lytix Biopharma AS might have .

Lytix Biopharma AS  (FRA:6BG) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Lytix Biopharma AS Tariff Resilience Score Related Terms

FRA:6BG
27GF Score
Lytix Biopharma AS FRA:6BG
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lytix Biopharma AS (FRA:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.74 is trading 3620% above its estimated GF Value™ of €0.02.

Key valuation signals for FRA:6BG:

  • Tariff Resilience Score: 0
  • GF Value™: €0.02 vs. price of €0.74 (3620% above fair value)
  • GF Score™: 27/100 with 1 warning sign

No single metric tells the full story. See the FRA:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
27GF Score

Get the complete analysis for FRA:6BG

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.74
Price
€0.02
GF Value